文献速递前列腺癌男科与性医学

促红细胞生成素对根治性前列腺切除术后勃起功能的影响:ERECT随机临床试验

Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
PubMed 文献 · J Urol · 2021-02-03

ERECT试验为2期双盲安慰剂对照随机试验,纳入56例双侧神经血管束保留根治性前列腺切除术患者,围手术期皮下注射促红细胞生成素(20,000单位)或安慰剂共3次。结果显示两组在6个月及其他时间点IIEF-EF评分无统计学显著差异,促红细胞生成素未改善勃起功能恢复。

要点

  • 围手术期短程促红细胞生成素未改善根治性前列腺切除术后勃起功能恢复。
  • 6个月时两组IIEF-EF评分差异无统计学意义(p=0.50)。
  • 神经保留评分极佳(10/10)与更好的IIEF-EF恢复相关(+5.2,p=0.022)。

核心结论

  • 在围手术期短程给药背景下,促红细胞生成素与安慰剂相比未改善根治性前列腺切除术患者的勃起功能恢复。

研究设计与样本

  • ERECT(NCT00737893)为2期双盲随机安慰剂对照试验,2017年7月至2019年12月进行。
  • 63例患者评估资格,56例随机分组(促红细胞生成素29例,安慰剂27例)。
  • 促红细胞生成素20,000单位或生理盐水安慰剂于术前1天、手术当天和术后1天皮下注射,共3次。

主要发现

  • IIEF-EF评分中位数从3个月时的12.5升至12个月时的24.5。
  • 2周血清血红蛋白中位数促红细胞生成素组高于安慰剂组(14.7 vs 13.6,p=0.02)。
  • 6个月时两组IIEF-EF评分无统计学显著差异(p=0.50),其他时间点亦无差异(混合模型回归系数:-1.7,95%CI -6.1-2.7,p=0.45)。
  • 神经保留评分极佳(10/10)与IIEF-EF恢复改善相关(+5.2,p=0.022)。
  • 两组其他患者报告的健康相关生活质量领域、肿瘤学结局和并发症在随访期间相似。

临床怎么用

  • 不推荐围手术期使用促红细胞生成素来改善根治性前列腺切除术后的勃起功能恢复。
  • 神经保留评分极佳(10/10)与更好的勃起功能恢复独立相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Erectile dysfunction significantly impacts quality of life for men undergoing radical prostatectomy for prostate cancer. Erythropoietin is a promising neurotrophic factor for neurogenic erectile dysfunction based on preclinical and retrospective data. MATERIALS AND METHODS: ERECT (NCT00737893) is a phase 2, double-blinded, randomized, placebo-controlled trial (July 2017-December 2019) evaluating the impact of perioperative erythropoietin on recovery of erectile function and other patient-reported, health-related quality of life outcomes after bilateral nerve-sparing radical prostatectomy (3, 6, 9, and 12 months). Erythropoietin (20,000 units) or saline placebo was injected subcutaneously the day before, day of, and day after surgery for 3 total doses. RESULTS: Of 63 patients assessed for eligibility, 56 patients were randomized. Arms (29 erythropoietin, 27 placebo) were well balanced (89.3% robotic, median age 55.5 years). International Index of Erectile Function-Erectile Function Domain (IIEF-EF) scores increased from median 12.5 at 3 months to 24.5 at 12 months. Median 2-week serum hemoglobin was higher for the erythropoietin arm compared to placebo (14.7 vs 13.6, p=0.02). There was no statistically significant difference in IIEF-EF scores at 6 months comparing erythropoietin to placebo (p=0.50) or at other time points (mixed model regression coefficient: -1.7, 95% CI -6.1-2.7, p=0.45). Excellent nerve-sparing rating (10/10) was associated with improved IIEF-EF recovery (+5.2, p=0.022). Other patient-reported, health-related quality of life domains as well as oncologic outcome and complications were similar between arms during followup. CONCLUSIONS: In the context of brief perioperative dosing, erythropoietin did not improve recovery of erectile function for men undergoing radical prostatectomy for prostate cancer compared to placebo. Further research to identify effective adjuncts to improve health-related quality of life for these men is needed.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Patel HD, Schwen ZR, Campbell JD, et al. Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. J Urol. 2021. PMID: 33530745. doi:10.1097/JU.0000000000001586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。